The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

HotCopper was live at the 2026 RIU Resources Round-Up Conference in Sydney, where editor Isaac McIntyre was joined by Adavale Resources (ASX:ADD) managing director David Ward to discuss the big re-evaluation going on at its flagship London-Victoria gold mine, and what it will mean for the explorer.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Tune in to the From the Floor interview (above) to hear Mr Ward’s hopes for the re-evaluation at the mine, how past drilling panned out, and when things could be wrapped up with the company’s plotted resource growth.

And, you can listen to all the rest of the 2026 RIU Sydney interviews here.

Join the discussion: See what HotCopper users are saying about Adavale Resources Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

add by the numbers
More From The Market Online
The Market Online Video

RIU Sydney LIVE: Alligator ‘very, very happy’ with FRT results from Samphire – and with the timing, too

HotCopper editor Isaac McIntyre speaks to Alligator Energy CEO Andrea Marsland-Smith live at the 2026 RIU…

Asara Resources raises $60M to fast track Kada gold exploration

Asara Resources has received firm commitments for an institutional placement to raise $60 million to support…
The Market Online Video

WATCH: HotCopper @ 2026 RIU Resources Round-Up − All our from-the-floor interviews

HotCopper was at the RIU Resources Round-Up in Sydney, talking to all the ASX-listed companies over…

Amplia Therapeutics and ANZGOG to undertake ovarian cancer study

Amplia Therapeutics and the ANZOG have entered into an agreement to conduct a new clinical study…